- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03639831
ACUTE AND CHRONIC EFFECTS OF A BOTANICAL EXTRACT ON ANXIETY, PERCEIVED STRESS, MOOD AND CORTISOL IN HEALTHY ADULTS
ACUTE AND CHRONIC EFFECTS OF A PROPRIETARY BOTANICAL EXTRACT ON ANXIETY, PERCEIVED STRESS, MOOD AND CORTISOL SECRETION AND METABOLISM IN HEALTHY ADULTS: RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND CLINICAL TRIAL
Mood disorders, including depression and anxiety, are one of the main causes of the overall disease burden worldwide.
In recent years, the efficacy of certain botanicals as an alternative solution for depression has been evaluated in a number of clinical trials.
However, only few studies looked at the effects of these botanicals on mood in healthy subjects.
The aim of the proposed randomised, double-blind, placebo-controlled, parallel groups methodology is to assess the acute and chronic effects of daily supplementation with a proprietary and standardized botanical extract in comparison to placebo in healthy adults aged 18-60 years with self-reported low mood.
Study Overview
Status
Conditions
Detailed Description
The chronic effect of the active product on mood, anxiety, perceived stress, quality of life and cortisol secretion & metabolism will be assessed through validated questionnaires and urine collection after 2, 4 and 8 weeks of daily supplementation.
The acute effect of the product will be assessed after a single dose and exposure to an acute psychological stressor. Before, during and after the stressor, saliva samples will be collected and subjective levels of anxiety and mood will be measured. In addition, Galvanic Skin Response (GSR) and heart rate (HR) will be measured throughout the stressor session.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Newcastle upon Tyne, United Kingdom, NE1 8ST
- Brain, Performance and Nutrition Research Centre, Northumbria University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
With non-pathological feelings of anxiety and/ or stress in daily life:
- Subjects self-reporting low mood;
- Total score ≥ 40 at the Profile of Mood State (POMS 2);
- Score < 16 at the Generalized Anxiety Disorder 7-item (GAD-7) questionnaire
- Score ≤ 10 at the Patient Health Questionnaire 9-item (PHQ-9)
- Not meeting the diagnosis criteria for any mental disorder
- Body Mass Index (BMI) in the normal range: 18.5 ≥ BMI ≤ 30 kg/ m2
- For non-menopausal women: using effective contraception/pregnancy is not physiologically possible.
- Subject showing no difficulty for salivary sampling
- Subjects capable of and willing to comply with the protocol and to give their written informed consent
Main Exclusion Criteria:
- Diagnosis of psychological pathology within the previous 3 years
- Diagnosis of cognitive pathology
- Anxiolytic or antidepressant treatment, within the previous 3 months
- Event likely to have impacted the subject's emotional and/ or psychological state within the last 8 weeks or planned during the next 8 weeks
- Menopausal transition
- High blood pressure
- Subjects diagnosed with diabetes, cardiovascular disease, recurrent infectious diseases or chronic inflammatory pathology
- Usual corticoid treatment/ steroidal anti-inflammatory treatment
- Unbalanced thyroid disease
- High physical activity practice
- Tobacco consumption
- Subjects consuming any food supplement
- Excessive alcohol or caffeine use
- Consumption of recreational drugs
- Subject currently participating in other clinical or nutrition intervention studies, or has done in the past 4 weeks.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Active group
Proprietary, standardized botanical extract
|
2 capsules/ day providing the proprietary botanical extract as unique active ingredient
|
Placebo Comparator: Placebo group
Placebo (maltodextrin)
|
2 capsules/ day providing no active component
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mood state
Time Frame: Week 8
|
Variation of the Profile of mood states (POMS-2) total score: TMD (Total Mood Disturbance score).
The POMS-2 is a scale which includes six mood subscales: Anger, Confusion, Depression, Fatigue, Tension, and Vigor.
Each subscale is scored between 0 and 100.
TMD is determined by summing the Negative Mood State subscores and subtracting the Vigor subscore (unique Positive Mood State subscale).
For each subscale except Vigor, a lower subscore indicates a better mood state.
For the Vigor subscale, a higher subscore indicates a better mood state.
A lower POMS-2 TMD indicates a better mood state.
|
Week 8
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
POMS-2 subscores
Time Frame: week 2, week 4, week 8
|
Variation of the POMS-2 subscores: Anger, Confusion, Depression, Fatigue, Tension, and Vigor.
Each subscale is scored between 0 and 100.
For each subscale except Vigor, a lower subscore indicates a better mood state.
For the Vigor subscale, a higher subscore indicates a better mood state.
|
week 2, week 4, week 8
|
Anxiety state State-Trait Anxiety Inventory
Time Frame: week 2, week 4, week 8
|
Variation of the State-Trait Anxiety Inventory (STAI-State) score.
Min score: 20; Max score: 80. Higher score corresponds to a higher level of anxiety.
|
week 2, week 4, week 8
|
Anxiety state according to the Hospital Anxiety and Depression Scale
Time Frame: week 2, week 4, week 8
|
Variation of the anxiety subscore of the Hospital Anxiety and Depression Scale (HADS-A).
Min score: 0; Max score: 21.
Higher score corresponds to a higher level of anxiety.
|
week 2, week 4, week 8
|
Percentage of responders
Time Frame: week 2, week 4, week 8
|
A responder is defined as a participant with a statistically significant reduction of the POMS-2 TMD T-score.
A lower POMS-2 TMD indicates a better mood state.
|
week 2, week 4, week 8
|
Psychological stress
Time Frame: week 2, week 4, week 8
|
Variation of the Perceived Stress Scale (PSS-10) score (min score: 0; max score: 40; a higher score corresponds to a lower psychological stress feeling)
|
week 2, week 4, week 8
|
Worry feeling
Time Frame: week 2, week 4, week 8
|
Variation of the Penn State Worry Questionnaire score (min score: 16; max score: 80; a higher score corresponds to a higher worry feeling)
|
week 2, week 4, week 8
|
Coping response to stress
Time Frame: week 2, week 4, week 8
|
Variations of the COPE inventory score (min score: 60; max score: 240).
A higher score indicates that the subject uses more coping strategies in response to stress.
|
week 2, week 4, week 8
|
Depressive-like state
Time Frame: week 2, week 4, week 8
|
Variation of the depression subscore of the HADS (HADS-D).
HADS-D score is comprised between 0 and 21.
A higher HADS-D score indicates a higher level of depression.
|
week 2, week 4, week 8
|
Quality of life score
Time Frame: week 2, week 4, week 8
|
Variation of the World Health Organisation Quality of Life questionnaire (WHOQOL-BREF) score, comprised between 16 and 80. Higher score indicates higher quality of life.
|
week 2, week 4, week 8
|
Cognitive performances
Time Frame: week 2, week 4, week 8
|
Variation of the performance on serial subtractions tasks: total and correct responses at serials 3s, 7s and 17s.
For Serial 3s: Participants will be instructed to count backwards in threes from a given number, as quickly and accurately as possible.
For Serial 7s: same task as for serial 3s but with the serial subtraction of 7. Serial 17s: same task as for serial 3s but with the serial subtraction of 17.
|
week 2, week 4, week 8
|
Cognitive performances
Time Frame: week 2, week 4, week 8
|
Variation of the performance on the tracking task : speed and accuracy.
In this task participants are required to use the mouse to move a cursor to attempt to track an asterisk which follows a random on-screen path.
The distance between the target and the cursor is then computed every 100 ms.
|
week 2, week 4, week 8
|
Diurnal cortisol secretion
Time Frame: week 2, week 4, week 8
|
Variation of cortisone/ cortisol urinary concentrations ratio
|
week 2, week 4, week 8
|
Diurnal cortisol metabolism
Time Frame: week 2, week 4, week 8
|
Variation of allo-tetrahydrocortisol (THFs)/ tetrahydrocortisone (THE) urinary concentrations ratio
|
week 2, week 4, week 8
|
Biological response to an acute stressor
Time Frame: week 2, week 4 & week 8; at 15, 30, 45, 60 & 75 min after exposure to the stressor
|
Incremental area under the curve (iAUC) of the salivary cortisol concentration and alpha-amylase activity
|
week 2, week 4 & week 8; at 15, 30, 45, 60 & 75 min after exposure to the stressor
|
Psychological response to an acute stressor assessed through the STAI
Time Frame: week 2, week 4 & week 8; 30 and 60 min after exposure to the stressor
|
Variation of the State-Trait Anxiety Inventory (STAI-State) score.
Min score: 20; Max score: 80. Higher score corresponds to a higher level of anxiety.
|
week 2, week 4 & week 8; 30 and 60 min after exposure to the stressor
|
Psychological response to an acute stressor assessed on a Visual Analogical Scale
Time Frame: week 2, week 4 & week 8; 30 and 60 min after exposure to the stressor
|
Variation of the perceived stress scores obtained at a Visual Analogical Scale (VAS).
Score range: 0-100.
Higher score indicates a higher level of anxiety.
|
week 2, week 4 & week 8; 30 and 60 min after exposure to the stressor
|
Hemodynamic response to an acute stressor
Time Frame: week 2, week 4 & week 8; 0 to 15 min after exposure to the stressor
|
Maximum increase and incremental area under the curve (iAUC) of the heart rate
|
week 2, week 4 & week 8; 0 to 15 min after exposure to the stressor
|
Galvanic Skin Response to the acute stressor
Time Frame: week 2, week 4 & week 8
|
Averaged raw score in microSiemens (µS) during exposure to acute stressor, likely to be comprised between 0.5 µS and 5 µS.
A higher GSR indicates a higher stress state.
|
week 2, week 4 & week 8
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Bioavaialability
Time Frame: week 2, week 4 & week 8
|
Urinary metabolites
|
week 2, week 4 & week 8
|
Biomarqueurs of oxidative damage
Time Frame: week 2, week 4 & week 8
|
Change in urine F2-isoprostane
|
week 2, week 4 & week 8
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: David KENNEDY, PhD, Brain, Performance and Nutrition Research Centre - Northumbria University
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PTC198-2017
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mood Disorders
-
Université du Québec a MontréalCiusss de L'Est de l'Île de Montréal; PhysioExtra; EnergirRecruitingDepression ; Anxiety With Depressed Mood ; Mood Disorder, Adjustment Disorder With Depressed MoodCanada
-
Joliet Center for Clinical ResearchAbbottCompleted
-
National Institute of Mental Health (NIMH)Completed
-
National Institute of Mental Health (NIMH)Completed
-
University of North Carolina, Chapel HillNational Institute of Mental Health (NIMH)Completed
-
University of Colorado, DenverCompletedMood Disorders | Irritable MoodUnited States
-
VA Office of Research and DevelopmentCompleted
-
Baskent UniversityZİYAFET UĞURLURecruitingDisaster; Personality | Disorder, MoodTurkey
-
Fayoum University HospitalCompletedKetamine-Induced Mood DisorderEgypt
-
Mayo ClinicCompletedMood Disorders in Children and AdolescentsUnited States
Clinical Trials on Proprietary, standardized botanical extract
-
Kemin Foods LCMusclePharm Sports Science InstituteCompletedSleep | Mood | Cognitive PerformanceUnited States
-
HealthQuiltCompletedImmune Function | Covid19 Positive Patient | Covid19 Close ContactUnited States
-
Milsing d.o.o.CompletedMild Cognitive Impairment | Cerebrovascular InsufficiencyCroatia
-
Antigen Laboratories, Inc.Completed
-
NovoBliss Research Pvt LtdCompletedBody Weight in the Overweight and Obese Class - I PopulationIndia
-
University of ZurichSwiss National Science Foundation; The Broad FoundationCompletedUlcerative ColitisSwitzerland
-
BiomixKyunghee UniversityCompletedAttention Deficit Hyperactivity DisorderKorea, Republic of
-
9305-9954 Quebec IncMcMaster UniversityWithdrawnChronic Pain | InsomniaCanada
-
Greer LaboratoriesCompletedAllergic RhinitisUnited States